Business Activities

Research and Development


Mochida's Research Center - targeting diabetes and obesity as its core fields and central nervous system (CNS) as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods.


Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our major specialities: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine, and psychiatry. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.


As of November 20,2015
Code Name Indications Formulation Stage Remarks
MLD-55 escitalopram Social anxiety disorder Oral Approved Licensed-in from Lundbeck [Denmark]
MD-0901 mesalazine Ulcerative colitis Oral Filed Licensed-in from Shire Pharmaceuticals Group
MJR-35 dienogest Uterine adenomyosis Oral Phase III Licensed-in from Jenapharm (Bayer HealthCare)[Germany]
Functional dysmenorrhea Phase II
LBEC0101 etanercept Rheumatoid arthritis Injection Phase III Biosimilar (Follow-on biologics)
Licensed-in from LG Life Sciences[Korea]